Compare Delta Air Lines, Inc. (DAL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs TG Therapeutics Inc — how do they compare? Delta Air Lines, Inc. trades at $89.99 (market cap $59.46B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Delta Air Lines, Inc. is far larger — about 7.8× TG Therapeutics Inc's market cap, and Delta Air Lines, Inc. pays a 0.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DAL | TGTX | |
|---|---|---|
Market Cap | $59.46B | $7.64B |
Sector | Industrials | Health |
52-Week High | $93.66 | $59.06 |
52-Week Low | $55.65 | $26.94 |
Enterprise Value | $74.77B | $7.84B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $90.14, up 1.04% on the day, with strong technical momentum and consistent earnings beats. The stock shows bullish moving average signals and trades near pivot point resistance at $91. Fundamentally, DAL reported Q2 2026 EPS of $1.56, beating estimates, with revenue growth to $63.36B in 2025 and a net margin of 5.78%. The company maintains robust cash flow from operations of $8.34B and a declining debt-to-asset ratio of 17.35% in 2025.
Outlook remains positive with an 81.82% analyst buy rating and a $108.27 consensus price target, implying 20% upside. Key risks include fuel cost volatility and competitive pressure, but DAL's premium travel demand and loyalty program strength support growth. Institutional sentiment is favorable despite recent insider sales, with net cash flow positive at $1.08B in 2025.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
